{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:40:01Z","timestamp":1787625601519,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","award":["297182"],"award-info":[{"award-number":["297182"]}],"id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cpcardiol.2022.101109","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T10:59:42Z","timestamp":1641553182000},"page":"101109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comorbidities with Familial Hypercholesterolemia (FH): A Systematic Review"],"prefix":"10.1016","volume":"48","author":[{"given":"Golnaz","family":"Vaseghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaghayegh Haghjooy","family":"Javanmard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyan","family":"Heshmat-Ghahdarijani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizal","family":"Sarrafzadegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2712-3839","authenticated-orcid":false,"given":"Atefeh","family":"Amerizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101109_bib0001","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/eurheartj\/eht015","article-title":"Diagnosis and treatment of familial hypercholesterolaemia","volume":"34","author":"Hovingh","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0002","first-page":"e29","article-title":"Heart disease and stroke statistics\u20132015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9913969","article-title":"Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry","volume":"2021","author":"Vaseghi","year":"2021","journal-title":"J Lipids"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0004","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1161\/CIRCRESAHA.114.302721","article-title":"Mechanisms of plaque formation and rupture","volume":"114","author":"Bentzon","year":"2014","journal-title":"Circulation Research"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3389\/fphar.2018.00707","article-title":"Familial hypercholesterolemia: new horizons for diagnosis and effective management","volume":"9","author":"Mytilinaiou","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0006","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","article-title":"Mechanisms of disease: genetic causes of familial hypercholesterolemia","volume":"4","author":"Soutar","year":"2007","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0007","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.atherosclerosis.2012.02.018","article-title":"Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients","volume":"222","author":"Slimani","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0008","first-page":"351","article-title":"Effectiveness of altering serum cholesterol levels without drugs","volume":"13","author":"Rosenthal","year":"2000","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0009","first-page":"169","article-title":"Familial hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0010","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0011","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fendo.2018.00261","article-title":"Depressive symptoms, co-morbidities, and glycemic control in Hong Kong Chinese elderly patients with type 2 diabetes mellitus","volume":"9","author":"Fung","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0013","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2147\/DMSO.S235546","article-title":"Association of dyslipidemia and comorbidities with risk factors among diabetic patients: a retrospective analysis","volume":"13","author":"Gazzaz","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0014","first-page":"337","article-title":"The impact of comorbidity on cancer and its treatment","volume":"66","author":"Sarfati","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/pubmed\/fdx072","article-title":"Do comorbidities influence help-seeking for cancer alarm symptoms? A population-based survey in England","volume":"40","author":"Salika","year":"2018","journal-title":"Journal of public health"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0016","doi-asserted-by":"crossref","first-page":"e587","DOI":"10.1161\/CIRCULATIONAHA.115.020701","article-title":"Heterozygous Familial Hypercholesterolemia","volume":"133","author":"Onorato","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0017","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(02)00330-1","article-title":"A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia","volume":"168","author":"Marks","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0019","article-title":"Familial hypercholesterolemia (FH) registry worldwide: A systematic review","author":"Amerizadeh","year":"2021","journal-title":"Current Problems in Cardiology"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0020","doi-asserted-by":"crossref","first-page":"19273","DOI":"10.1038\/s41598-019-55682-x","article-title":"Lower risk of smoking-related cancer in individuals with familial hypercholesterolemia compared with controls: a prospective matched cohort study","volume":"9","author":"Krogh","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0021","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1093\/eurheartj\/ehn422","article-title":"Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"29","author":"Neil","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0022","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0023","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jacl.2018.09.008","article-title":"Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia","volume":"13","author":"Paquette","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0024","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2337\/db17-0173","article-title":"Familial Hypercholesterolemia and Type 2 Diabetes in the Old Order Amish","volume":"66","author":"Xu","year":"2017","journal-title":"Diabetes."},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0025","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacl.2015.08.005","article-title":"Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes\/diabetes risk","volume":"9","author":"Saavedra","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0026","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/2047487319896138","article-title":"Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia","volume":"27","author":"Perez-Calahorra","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0027","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5551\/jat.45070","article-title":"Efficacy and safety of alirocumab in Japanese patients with diabetes mellitus: post-hoc sub analysis of ODYSSEY Japan","volume":"26","author":"Teramoto","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0028","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1038\/s41598-017-06101-6","article-title":"Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia","volume":"7","author":"Climent","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0029","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijcard.2015.07.107","article-title":"Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study","volume":"201","author":"Fuentes","year":"2015","journal-title":"Inter J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2014.08.047","article-title":"Statin therapy and risk of diabetes in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia","volume":"237","author":"Skoumas","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0031","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40618-018-0959-0","article-title":"Clinical and genetic characteristics of familial hypercholesterolemia patients with type 2 diabetes","volume":"42","author":"Sun","year":"2019","journal-title":"J Endocrinolog Invest"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0032","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.atherosclerosis.2018.06.011","article-title":"Latvian registry of familial hypercholesterolemia: the first report of three-year results","volume":"277","author":"Latkovskis","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0033","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jacl.2020.12.001","article-title":"Familial hypercholesterolemia in Mexico: Initial insights from the national registry","volume":"15","author":"Mehta","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0034","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2019.06.899","article-title":"The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary center: Results from the TERCET registry with 19,781 individuals","volume":"288","author":"Dyrbu\u015b","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9913969","article-title":"Familial Hypercholesterolemia (FH) in Iran: Findings from the Four-Year FH Registry","volume":"2021","author":"Vaseghi","year":"2021","journal-title":"J Lipids"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0036","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.atherosclerosis.2018.08.010","article-title":"High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry","volume":"277","author":"B\u00e9liard","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251560","article-title":"Familial Hypercholesterolemia in the Arabian Gulf Region: Clinical results of the Gulf FH Registry","volume":"16","author":"Alhabib","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0038","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/01.HYP.36.5.808","article-title":"Renin-angiotensin system polymorphisms and coronary events in familial hypercholesterolemia","volume":"36","author":"Wierzbicki","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0039","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1210\/jc.2018-01058","article-title":"Familial hypercholesterolemia and risk of peripheral arterial disease and chronic kidney disease","volume":"103","author":"Emanuelsson","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ijcard.2015.08.146","article-title":"Elevated lipoprotein(a), hypertension and renal insufficiency as predictors of coronary artery disease in patients with genetically confirmed heterozygous familial hypercholesterolemia","volume":"201","author":"Chan","year":"2015","journal-title":"Intern J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0041","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1253\/circj.68.623","article-title":"Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia","volume":"68","author":"Yagi","year":"2004","journal-title":"Circ J"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0042","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nefroe.2018.09.003","article-title":"Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis","volume":"39","author":"Gonz\u00e1lez Sanchidri\u00e1n","year":"2019","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0043","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A historical perspective on the discovery of statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0044","first-page":"8","article-title":"Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease","volume":"6","author":"Visconti","year":"2016","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-001107","article-title":"Incidence of type 2 diabetes in familial combined hyperlipidemia","volume":"8","author":"Brouwers","year":"2020","journal-title":"BMJ Open Diabetes Research &amp; Care."},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0046","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0047","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0048","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ijcard.2017.07.081","article-title":"Incidence of cardiovascular events and vascular interventions in patients with type 2 diabetes","volume":"248","author":"Engelen","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0049","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1007\/s00125-015-3525-8","article-title":"Pathophysiology of diabetic dyslipidaemia: where are we?","volume":"58","author":"Verg\u00e8s","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jacl.2018.10.012","article-title":"Risk factors for cardiovascular disease in heterozygous familial hypercholesterolemia: A systematic review and meta-analysis","volume":"13","author":"Akioyamen","year":"2019","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0051","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0052","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-2002-32150","article-title":"Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia","volume":"110","author":"Geiss","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0053","doi-asserted-by":"crossref","first-page":"306","DOI":"10.24095\/hpcdp.39.11.03","article-title":"At-a-glance - Twenty years of diabetes surveillance using the Canadian Chronic Disease Surveillance System","volume":"39","author":"LeBlanc","year":"2019","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"10.1016\/j.cpcardiol.2022.101109_bib0054","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1573402115666190118142818","article-title":"Prevalence of HTN in Iran: Meta-analysis of Published Studies in 2004-2018","volume":"15","author":"Oori","year":"2019","journal-title":"Curr Hypertens Rev"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622000081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:20:10Z","timestamp":1758939610000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622000081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0146280622000081"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101109","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities with Familial Hypercholesterolemia (FH): A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101109"}}